The ECHELON-2 Trial: Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A plus CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+Peripheral T-Cell Lymphomas

Steven M. Horwitz, Owen A. O'Connor, Barbara Pro, Tim M. Illidge, Michelle A. Fanale, Ranjana H. Advani, Nancy L. Bartlett, Jacob Haaber Christensen, Franck Morschhauser, Eva Domingo-Domenech, Giuseppe Rossi, Won Seog Kim, Tatyana A. Feldman, Anne Lennard, David Belada, Arpad Illes, Kensei Tobinai, Kunihiro Tsukasaki, Su-Peng Yeh, Andrei R. ShustovAndreas Huettmann, Kerry J. Savage, Sam Yuen, Pier Luigi Zinzani, Zhaowei Hua, Meredith Little, Shangbang Rao, Joseph Woolery, Thomas Manley, Lorenz Truemper

Research output: Contribution to journalConference abstract in journalResearch

Original languageEnglish
JournalBlood
Volume132
Issue numberSuppl. 1
ISSN0006-4971
DOIs
Publication statusPublished - 29. Nov 2018
Event60th ASH Annual Meeting - San Diego, United States
Duration: 1. Dec 20184. Dec 2018

Conference

Conference60th ASH Annual Meeting
Country/TerritoryUnited States
CitySan Diego
Period01/12/201804/12/2018

Cite this